{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:09:58Z","timestamp":1764828598005},"reference-count":27,"publisher":"Cambridge University Press (CUP)","issue":"02","license":[{"start":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T00:00:00Z","timestamp":1509321600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creative%20commons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec id=\"S1092852917000761_abs1\" sec-type=\"general\"><jats:title>Background<\/jats:title><jats:p>Vortioxetine is an approved antidepressant that has also demonstrated positive effects on anxiety symptoms in subjects with generalized anxiety disorder (GAD). This post-hoc analysis evaluates the efficacy of vortioxetine in GAD subjects who are working and\/or pursuing an education.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852917000761_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>In study NCT00744627, 301 GAD subjects were randomized to vortioxetine 5 mg or placebo for 8 weeks. Efficacy measures included the Hamilton Anxiety Rating Scale (HAM\u2013A) total score, response\/remission, global functioning (Sheehan Disability Scale [SDS]), and quality of life (Short Form\u201336 Health Survey). In study NCT00788034, 687 GAD subjects were treated open-label with vortioxetine 5 or 10 mg for 20 weeks, after which subjects in remission were randomized to fixed-dose of vortioxetine (5 or 10 mg) or placebo for at least 24 weeks. The primary endpoint was time to relapse. Analyses were completed in subjects working and\/or pursuing an education at study entry and the full analysis set.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852917000761_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>In study NCT00744627, the effect of vortioxetine versus placebo on HAM\u2013A total score was \u20134.3 (<jats:italic>p<\/jats:italic>=0.0005) in working subjects (60% of total), while the effect in the total population was \u20133.8 (<jats:italic>p<\/jats:italic>=0.0001). The effect was greatest in subjects in professional (\u20134.5,<jats:italic>p<\/jats:italic>=0.0130) and associate professional positions (\u20137.6,<jats:italic>p<\/jats:italic>=0.0086). Greater effects in terms of response, remission, and the SDS and SF\u201336 were also observed. In NCT00788034, working subjects (69% of total) randomized to placebo were significantly more likely to relapse than subjects treated with vortioxetine (hazard ratio=2.9;<jats:italic>p<\/jats:italic>&amp;lt;0.001), while the hazard ratio in the total population was 2.7 (<jats:italic>p<\/jats:italic>&amp;lt;0.0001).<\/jats:p><\/jats:sec><jats:sec id=\"S1092852917000761_abs4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>The beneficial effects of vortioxetine on anxiety symptoms, functioning, and quality of life are greater in adults with GAD who are working and\/or pursuing an education versus the full GAD study population.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852917000761","type":"journal-article","created":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T02:52:26Z","timestamp":1509331946000},"page":"249-257","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of vortioxetine in working patients with generalized anxiety disorder"],"prefix":"10.1017","volume":"24","author":[{"given":"Michael Cronquist","family":"Christensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Loft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Florea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2017,10,30]]},"reference":[{"key":"S1092852917000761_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2010.08.040"},{"key":"S1092852917000761_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.brat.2017.01.014"},{"key":"S1092852917000761_ref17","doi-asserted-by":"publisher","DOI":"10.1080\/03630242.2016.1150385"},{"key":"S1092852917000761_ref16","doi-asserted-by":"publisher","DOI":"10.1136\/oem.56.5.302"},{"key":"S1092852917000761_ref15","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826110-00008"},{"key":"S1092852917000761_ref9","doi-asserted-by":"publisher","DOI":"10.1136\/jech.49.1.48"},{"key":"S1092852917000761_ref14","first-page":"115","volume":"78","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"S1092852917000761_ref8","doi-asserted-by":"publisher","DOI":"10.2307\/2392498"},{"key":"S1092852917000761_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2015.02.017"},{"key":"S1092852917000761_ref7","doi-asserted-by":"publisher","DOI":"10.1037\/1076-8998.12.4.334"},{"key":"S1092852917000761_ref12","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283530ad7"},{"key":"S1092852917000761_ref6","doi-asserted-by":"publisher","DOI":"10.1037\/1076-8998.1.1.27"},{"key":"S1092852917000761_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.07.012"},{"key":"S1092852917000761_ref5","volume-title":"Healthy Work: Stress Productivity and the Reconstruction of Working Life","year":"1990"},{"key":"S1092852917000761_ref10","doi-asserted-by":"publisher","DOI":"10.1136\/jech.56.6.450"},{"key":"S1092852917000761_ref4","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200015060-00002"},{"key":"S1092852917000761_ref3","doi-asserted-by":"publisher","DOI":"10.1002\/da.1020"},{"key":"S1092852917000761_ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.617"},{"key":"S1092852917000761_ref1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1176\/ajp.156.12.1915","volume":"156","year":"1999","journal-title":"Am J Psychiatry"},{"key":"S1092852917000761_ref27","first-page":"24","volume":"63","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"S1092852917000761_ref26","doi-asserted-by":"publisher","DOI":"10.1002\/da.20074"},{"key":"S1092852917000761_ref25","doi-asserted-by":"publisher","DOI":"10.1002\/da.20257"},{"key":"S1092852917000761_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2011.11.014"},{"key":"S1092852917000761_ref23","first-page":"2025","volume":"22","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"S1092852917000761_ref22","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145714000546"},{"key":"S1092852917000761_ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0263-x"},{"key":"S1092852917000761_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.07.001"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852917000761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T20:30:16Z","timestamp":1659731416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852917000761\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,30]]},"references-count":27,"journal-issue":{"issue":"02","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1092852917000761"],"URL":"https:\/\/doi.org\/10.1017\/s1092852917000761","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,30]]}}}